Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Immutep To Present Abstracts Evaluating First-In-Class MHCClass II Agonist, Eftilagimod Alfa, At European Society For Medical Oncology Congress 2025

Author: Benzinga Newsdesk | July 28, 2025 08:05am

Posted In: IMMP